Multi-target Chronic Pain Therapeutic

About Lohocla Research

Lohocla Research is a private, preclinical-stage biotech targeting chronic pain and addiction through a novel multi-target therapeutic platform. Founded by renowned alcohol and addiction researcher Dr. Boris Tabakoff, the company leverages deep neuroscience expertise to design molecules that address the complex, multi-system nature of these disorders. While still pre-revenue, its approach aims to improve efficacy and safety over single-target drugs in large, underserved patient markets. Key risks include typical preclinical development challenges and future capital needs.

Therapeutic Areas